Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 40, 2010 - Issue 6
Submit an article Journal homepage
212
Views
13
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey

D. J. SweenyDepartments of Drug Metabolism and Pharmacokinetics, and Development, Rigel Pharmaceuticals, South San Francisco, CA, USACorrespondence[email protected]
,
W. LiDepartments of Drug Metabolism and Pharmacokinetics, and Development, Rigel Pharmaceuticals, South San Francisco, CA, USA
,
E. GrossbardDepartments of Drug Metabolism and Pharmacokinetics, and Development, Rigel Pharmaceuticals, South San Francisco, CA, USA
&
D. T.W. LauDepartments of Drug Metabolism and Pharmacokinetics, and Development, Rigel Pharmaceuticals, South San Francisco, CA, USA
Pages 415-423 | Received 28 Dec 2009, Accepted 26 Feb 2010, Published online: 23 Apr 2010

References

  • Adlercreutz H. (2007). Lignans and human health. Crit Rev Clin Lab Sci 44(5–6):483–525.
  • Berman MH, Frazer AC (1992). Importance of tetrahydrofolate and ATP in the anaerobic O-demethylation reaction for phenylmethylethers. Appl Environ Microbiol. 58(3):925–31.
  • Blair RM, Appt SE, Franke AA, Clarkson TB. (2003). Treatment with antibiotics reduced plasma equol concentration in cynomolgus monkeys (Macaca fascicularis). J Nutr. 133:2262–76.
  • Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. (2006). R406, an orally available spleen tyrosine kinase inhibitor block Fc receptor signalling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 319:998–1008.
  • Eeckhaut E, Struijs K, Possemiers S, Vincken J-P, de Keukeleire, D, Verstraete W. (2008). Metabolism of the lignan macromolecule into enterolignans in the gastrointestinal lumen as determined in the simulator of the human intestinal ecosystem. J Agricult Food Chem. 56(12):4806–12.
  • Fleisher D, Stewart BH, Amidon GL. (1985). Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. Meth Enzymol. 112:360–81.
  • Heider J, Fuchs G. (1997). Anaerobic metabolism of aromatic compounds. Eur J Biochem. 243:577–96.
  • Pine PR, Chang B, Schoettler N, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E. (2007). Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 124(3):244–57.
  • Singh R, Masuda ES. (2007). Spleen tyrosine kinase (SYK) biology, inhibitors and therapeutic applications. Ann Rep Med Chem. 42:379–91.
  • Sweeny DJ, Li W, Baluom M, Park G, Bhaamidipati S, Clough J, Singh R, Grossbard E, Lau D. (Forthcoming 2010) Metabolism of the active spleen tyrosine kinase (Syk) inhibitor R940406 in humans following administration of the oral prodrug R935788: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos.
  • Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. (2000). Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 21(3):148–54.
  • Wang L-Q, Meselhy, MR, Li Y, Nakamura N, Min B-S Qin, G-W, Hattori M. (2001). The heterocyclic ring fission and dehydroxylation of catechins and related compounds by Eubacterium sp. strain SDG-2, a human intestinal bacterium. Chem Pharm Bull. 49(12):1640–3.
  • Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Musser TK, Straniero N, Vincente-Gonzales AV, Grossbard E. (2008). Treatment of rheumatoid arthritis with a SYK kinase inhibitor: a twelve week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11):3309–18.
  • White GF, Russell NJ, Tidswell EC. (1996). Bacterial scission of ether bonds. Microbiol Rev. 60(1):216–32.
  • Wong BR, Grossbard EB, Payan DG, Masuda ES. (2004). Targeting SYK as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13(7):743–62.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.